Free Trial
OTCMKTS:IDXG

Interpace Biosciences (IDXG) Stock Price, News & Analysis

Interpace Biosciences logo
$6.05 0.00 (0.00%)
As of 11/13/2026 12:31 PM Eastern

About Interpace Biosciences Stock (OTCMKTS:IDXG)

Advanced

Key Stats

Today's Range
$6.05
▼
$6.15
50-Day Range
$4.95
▼
$8.50
52-Week Range
$4.95
▼
$7.45
Volume
441 shs
Average Volume
1,539 shs
Market Capitalization
$33.53 million
P/E Ratio
15.13
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Interpace Biosciences is a molecular diagnostics company that develops and provides tests to help clinicians assess cancer risk and guide treatment decisions. Its services combine molecular analysis with pathology and related diagnostic expertise.

The company’s tests focus on conditions including pancreatic cysts and thyroid nodules. Its offerings have included PancraGEN for pancreatic cyst assessment, as well as ThyGeNEXT and ThyraMIR for evaluating thyroid nodules. Interpace has also offered molecular testing for gastrointestinal cancers.

Interpace Biosciences, formerly known as PDI, Inc., serves healthcare providers and patients primarily in the United States through its diagnostic testing services.

AI Generated. May Contain Errors.

Interpace Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
18th Percentile Overall Score

IDXG MarketRank™: 
0.91259298618 of 5 stars

Interpace Biosciences scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Interpace Biosciences.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Interpace Biosciences is 15.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.37.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Interpace Biosciences is 15.13, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.59.

  • Price to Book Value per Share Ratio

    Interpace Biosciences has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.00% of the float of Interpace Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Interpace Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Interpace Biosciences has recently increased by 550.00%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Interpace Biosciences does not currently pay a dividend.

  • Dividend Growth

    Interpace Biosciences does not have a long track record of dividend growth.

  • News Sentiment

    Interpace Biosciences has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Interpace Biosciences this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Interpace Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    0.93% of the stock of Interpace Biosciences is held by insiders.

  • Percentage Held by Institutions

    5.73% of the stock of Interpace Biosciences is held by institutions.

  • Read more about Interpace Biosciences' insider trading history.
Receive IDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IDXG Stock News Headlines

PDI: High Yield, Persistent Risks, But I'm Staying Invested
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Headlines

IDXG Stock Analysis - Frequently Asked Questions

Interpace Biosciences' stock was trading at $6.1510 at the beginning of the year. Since then, IDXG stock has decreased by 1.6% and is now trading at $6.05.

Interpace Biosciences, Inc. (OTCMKTS:IDXG) issued its quarterly earnings results on Monday, August, 10th. The business services provider reported $0.05 earnings per share for the quarter. The business services provider had revenue of $9.13 million for the quarter. Interpace Biosciences had a net margin of 67.64% and a trailing twelve-month return on equity of 145.40%.

Shares of Interpace Biosciences reverse split before market open on Thursday, August 27th 2026.The 1-5 reverse split was announced on Thursday, August 27th 2026. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 27th 2026. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Shares of IDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Interpace Biosciences investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Catalyst Pharmaceuticals (CPRX), Block (XYZ), Johnson & Johnson (JNJ) and NVIDIA (NVDA).

Company Calendar

Last Earnings
8/10/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Services
Current Symbol
OTCMKTS:IDXG
CIK
1054102
Employees
102
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
$0.40
Trailing P/E Ratio
15.13
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$24.58 million
Net Margins
67.64%
Pretax Margin
11.06%
Return on Equity
145.40%
Return on Assets
87.36%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.22
Quick Ratio
2.22

Sales & Book Value

Annual Sales
$38.73 million
Price / Sales
0.87
Cash Flow
$28.81 per share
Price / Cash Flow
0.21
Book Value
$25.25 per share
Price / Book
0.24

Miscellaneous

Outstanding Shares
5,542,000
Free Float
5,490,000
Market Cap
$33.53 million
Optionable
Not Optionable
Beta
0.67
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (OTCMKTS:IDXG) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners